Further, the fact that tau-inclusions have been confirmed in FTD, CBD and PSP have made some authors indicate that the pathology of FTD should be divided into tau-positive and tau-negative variations and that the clinical picture only differs, again, because of the affected brain regions [8,9]. This evidence concerns the gene MAPT and frontotemporal dementia.